Journey Medical
DERM
71 hedge funds and large institutions have $75.5M invested in Journey Medical in 2026 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 23 closing their positions.
3,917% more call options, than puts
Call options by funds: $241K | Put options by funds: $6K
35% more capital invested
Capital invested by funds: $55.8M → $75.5M (+$19.7M)
0% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 23
1% less funds holding
Funds holding: 72 → 71 (-1)
6.13% less ownership
Funds ownership: 55.63% → 49.5% (-6.1%)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$4.14M |
| 2 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
+$3.06M |
| 3 |
Jane Street
New York
|
+$1.83M |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$818K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$799K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.98M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.48M |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$2.32M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$2.07M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.75M |
DERM Hedge Fund Activity: Q2 2026 in Review
71 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Journey Medical (DERM) for Q2 2026, worth a combined $75.5M — up 35% from $55.8M a quarter earlier.
Fund positioning in DERM was balanced in Q2 2026: 23 funds opened new positions, 23 closed out, 19 added to existing stakes and 23 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $4.14M. The largest seller was BlackRock, cutting an estimated $4.98M.
- 71 institutional investors held Journey Medical (DERM) as of Q2 2026, down from 72 in Q1 2026.
- Funds reported $75.5M of Journey Medical stock for Q2 2026, up 35% quarter-over-quarter.
- 23 funds opened new Journey Medical positions in Q2 2026 and 23 closed out, a net change of 0 holders.
- The largest Journey Medical buyer in Q2 2026 was Wasatch Advisors, an estimated $4.14M added.
- The largest Journey Medical seller in Q2 2026 was BlackRock, an estimated $4.98M sold.
Based on aggregated 13F filings for Q2 2026.